TG Therapeutics stock upgraded at Goldman Sachs on selloff

Business on Wall Street in Manhattan


Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

Following a 49% decline in the previous session, TG Therapeutics (NASDAQ:TGTX) traded modestly higher in the pre-market Wednesday after Goldman Sachs upgraded the biotech, citing a valuation in line with commercial prospects for the company’s multiple sclerosis therapy, Briumvi.

Raising

Leave a Reply

Your email address will not be published. Required fields are marked *